Hemodynamic characterization of left ventricular function in experimental coxsackieviral myocarditis: Effects of carvedilol and metoprolol

European Journal of Pharmacology

Volumn 491, Issue 2-3, 2004, Pages 173-179

  Tschöpe, Carsten ^a   Westermann, Dirk ^a   Steendijk, Paul ^b   Noutsias, Michael ^a   Rutschow, Susanne ^a   Weitz, Anneke ^a   Schwimmbeck, Peter Lothar ^a   Schultheiss, Heinz Peter ^a   Pauschinger, Matthias ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adrenoceptor; Conductance; Myocarditis; Pressure volume loops

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; METOPROLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS; COXSACKIE VIRUS INFECTION; DIASTOLE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ELECTRIC CONDUCTIVITY; EXPERIMENT; HEART AFTERLOAD; HEART INDEX; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONTRACTILITY; HEMODYNAMICS; INOCULATION; MALE; MOUSE; MOUSE STRAIN; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; SYSTOLE;

ANIMALS; CARBAZOLES; COXSACKIEVIRUS INFECTIONS; MALE; METOPROLOL; MICE; MICE, INBRED BALB C; MYOCARDITIS; PROPANOLAMINES; VENTRICULAR FUNCTION, LEFT;

EID: 2342454376     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.03.032     Document Type: Article

References (30)

1. Afanasyeva M.R.N. Immune mediators in inflammatory heart disease: insights from a mouse model. Eur. Heart J. 2002:2002;I31-I36
2. Alvarez B.V., Perez N.G., Ennis I.L., Camilion de Hurtado M.C., Cingolani H.E. Mechanisms underlying the increase in force and Ca(2+) transient that follow stretch of cardiac muscle: a possible explanation of the Anrep effect. Circ. Res. 85:1999;716-722
3. Andersson B., Caidahl K., di Lenarda A., Warren S.E., Goss F., Waldenstrom A., Persson S., Wallentin I., Hjalmarson A., Waagstein F. Changes in early and late diastolic filling patterns induced by long-term adrenergic beta-blockade in patients with idiopathic dilated cardiomyopathy. Circulation. 94:1996;673-682
4. Bohm M., Maack C. Treatment of heart failure with beta-blockers. Mechanisms and results. Basic Res. Cardiol. 95(Suppl 1):2000;I15-I24
5. Bristow M.R. What type of beta-blocker should be used to treat chronic heart failure? Circulation. 102:2000;484-486
6. Eichhorn E.J., Bristow M.R. The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Curr. Control. Trials, Cardiovasc. Med. 2:2001;20-23
7. Eichhorn E.J., Bedotto J.B., Malloy C.R., Hatfield B.A., Deitchman D., Brown M., Willard J.E., Grayburn P.A. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation. 82:1990;473-483
8. Feuerstein G.Z. Apoptosis - new opportunities for novel therapeutics for heart diseases. Cardiovasc. Drugs Ther. 15:2001;547-551
9. Georgakopoulos D., Mitzner W.A., Chen C.H., Byrne B.J., Millar H.D., Hare J.M., Kass D.A. In vivo murine left ventricular pressure-volume relations by miniaturized conductance micromanometry. Am. J. Physiol. 274:1998;H1416-H1422
10. Herzum M., Weller R., Jomaa H., Wietrzychowski F., Pankuweit S., Mahr P., Maisch B. Left ventricular hemodynamic parameters in the course of acute experimental coxsackievirus B3 myocarditis. J. Mol. Cell. Cardiol. 27:1995;1573-1580
11. Huber S.A. Coxsackievirus-induced myocarditis is dependent on distinct immunopathogenic responses in different strains of mice. Lab. Invest. 76:1997;691-701
12. Huber S.A., Pfaeffle B. Differential Th1 and Th2 cell responses in male and female BALB/c mice infected with coxsackievirus group B type 3. J. Virol. 68:1994;5126-5132
13. Huber S.A., Polgar J., Schultheiss P., Schwimmbeck P. Augmentation of pathogenesis of coxsackievirus B3 infections in mice by exogenous administration of interleukin-1 and interleukin-2. J. Virol. 68:1994;195-206
14. Kanda T., Adachi H., Ohno T., Suzuki T., Murata K. Myocardial beta-receptor and cardiac angiotensin alterations during the acute and chronic phases of viral myocarditis. Eur. Heart J. 15:1994;686-690
15. Kass D.A., Maughan W.L., Guo Z.M., Kono A., Sunagawa K., Sagawa K. Comparative influence of load versus inotropic states on indexes of ventricular contractility: experimental and theoretical analysis based on pressure-volume relationships. Circulation. 76:1987;1422-1436
16. Li J., Schwimmbeck P.L., Tschope C., Leschka S., Husmann L., Rutschow S., Reichenbach F., Noutsias M., Kobalz U., Poller W., Spillmann F., Zeichhardt H., Schultheiss H.P., Pauschinger M. Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovasc. Res. 56:2002;235-247
17. MERIT-HF-Group Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 353:1999;2001-2007
18. Nishio R., Sasayama S., Matsumori A. Left ventricular pressure-volume relationship in a murine model of congestive heart failure due to acute viral myocarditis. J. Am. Coll. Cardiol. 40:2002;1506-1514
19. Nishio R., Shioi T., Sasayama S., Matsumori A. Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus. J. Am. Coll. Cardiol. 41:2003;340-345
20. Panina-Bordignon P., Mazzeo D., Lucia P.D., D'Ambrosio D., Lang R., Fabbri L., Self C., Sinigaglia F. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J. Clin. Invest. 100:1997;1513-1519
21. Pauschinger M., Bowles N.E., Fuentes-Garcia F.J., Pham V., Kuhl U., Schwimmbeck P.L., Schultheiss H.P., Towbin J.A. Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Circulation. 99:1999;1348-1354
22. Poole-Wilson P.A., Swedberg K., Cleland J.G., Di Lenarda A., Hanrath P., Komajda M., Lubsen J., Lutiger B., Metra M., Remme W.J., Torp-Pedersen C., Scherhag A., Skene A. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 362:2003;7-13
23. Popovic Z., Miric M., Vasiljevic J., Sagic D., Bojic M., Popovic A.D. Acute hemodynamic effects of metoprolol±nitroglycerin in patients with biopsy-proven lymphocytic myocarditis. Am. J. Cardiol. 81:1998;801-804
24. Seong I.W., Choe S.C., Jeon E.S. Fulminant coxsackieviral myocarditis. N. Engl. J. Med. 345:2001;379
25. Shioi T., Matsumori A., Sasayama S. Persistent expression of cytokine in the chronic stage of viral myocarditis in mice. Circulation. 94:1996;2930-2937
26. Sponer G., Bartsch W., Strein K., Muller-Beckmann B., Bohm E. Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties. J. Cardiovasc. Pharmacol. 9:1987;317-327
27. Steendijk P., Baan J. Comparison of intravenous and pulmonary artery injections of hypertonic saline for the assessment of conductance catheter parallel conductance. Cardiovasc. Res. 46:2000;82-89
28. Watanabe K., Takahashi T., Nakazawa M., Wahed M.I., Fuse K., Tanabe N., Kodama M., Aizawa Y., Ashino H., Tazawa S. Effects of carvedilol on cardiac function and cardiac adrenergic neuronal damage in rats with dilated cardiomyopathy. J. Nucl. Med. 43:2002;531-535
29. Yokoyama T., Arai M., Sekiguchi K., Tanaka T., Kanda T., Suzuki T., Nagai R. Tumor necrosis factor-alpha decreases the phosphorylation levels of phospholamban and troponin I in spontaneously beating rat neonatal cardiac myocytes. J. Mol. Cell. Cardiol. 31:1999;261-273
30. Yue T.L., Cheng H.Y., Lysko P.G., McKenna P.J., Feuerstein R., Gu J.L., Lysko K.A., Davis L.L., Feuerstein G. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J. Pharmacol. Exp. Ther. 263:1992;92-98